3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma
1
Interventions
Carboplatin
18
Cisplatin
14
pembrolizumab
13
durvalumab
11
Pemetrexed
11
Paclitaxel
11
Nivolumab
11
Gemcitabine
11
Rituximab
9
trastuzumab deruxtecan
7
osimertinib
6
olaparib
6
Dexamethasone
6
Capecitabine
6
atezolizumab
5
acalabrutinib
5
Specimen Handling
5
Lenalidomide
5
Bevacizumab
5
130-nm albumin-bound paclitaxel
5
tremelimumab
4
niraparib
4
cabozantinib
4
amivantamab
4
Prednisone
4
Oxaliplatin
4
Leucovorin
4
Ipilimumab
4
Fulvestrant
4
Docetaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Has announcements
×
tepotinib
×
Clear all
NCT02864992
2026-04-13
VISION
EMD Serono
Phase 2
Active not recruiting
337 enrolled
13 charts
2 FDA